Arend Mosterd
About
Arend Mosterd is a scholar working on Cardiology and Cardiovascular Medicine, Radiology, Nuclear Medicine and Imaging and Molecular Biology.
According to data from OpenAlex, Arend Mosterd has authored 138 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 100 papers in Cardiology and Cardiovascular Medicine, 36 papers in Radiology, Nuclear Medicine and Imaging and 27 papers in Molecular Biology. Recurrent topics in Arend Mosterd's work include Cardiac Imaging and Diagnostics (35 papers), Cardiovascular Effects of Exercise (34 papers) and Cardiovascular Function and Risk Factors (25 papers). Arend Mosterd is often cited by papers focused on Cardiac Imaging and Diagnostics (35 papers), Cardiovascular Effects of Exercise (34 papers) and Cardiovascular Function and Risk Factors (25 papers). Arend Mosterd collaborates with scholars based in Netherlands, United States and Canada. Arend Mosterd's co-authors include Arno W. Hoes, Frans H. Rutten, Amy Groenewegen, Pieter A. Doevendans, Birgitta K. Velthuis, Niek H. J. Prakken, Diederick E. Grobbee, Maarten J. Cramer, Arnoud W.J. van ‘t Hof and Thijs M.H. Eijsvogels and has published in prestigious journals such as New England Journal of Medicine, Circulation and SHILAP Revista de lepidopterología.
In The Last Decade
Arend Mosterd
127 papers receiving 5.7k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Arend Mosterd Netherlands | 34 | 4.2k | 926 | 837 | 810 | 476 | 138 | 5.9k | ||
| Grzegorz Opolski Poland | 38 | 5.9k 1.4× | 1.6k 1.7× | 828 1.0× | 728 0.9× | 883 1.9× | 634 | 8.1k | ||
| Filippos Triposkiadis Greece | 35 | 3.8k 0.9× | 741 0.8× | 591 0.7× | 570 0.7× | 633 1.3× | 217 | 5.4k | ||
| Dimitrios Farmakis Greece | 46 | 3.4k 0.8× | 936 1.0× | 729 0.9× | 580 0.7× | 428 0.9× | 245 | 7.2k | ||
| Kenneth Dickstein Norway | 33 | 5.7k 1.3× | 871 0.9× | 666 0.8× | 577 0.7× | 449 0.9× | 105 | 7.1k | ||
| Maarten J. Cramer Netherlands | 39 | 4.5k 1.1× | 1.1k 1.2× | 421 0.5× | 960 1.2× | 557 1.2× | 273 | 6.2k | ||
| Franz Weidinger Austria | 33 | 2.2k 0.5× | 1.3k 1.4× | 640 0.8× | 643 0.8× | 291 0.6× | 122 | 4.2k | ||
| Steen Z. Abildstrøm Denmark | 36 | 4.1k 1.0× | 1.3k 1.4× | 392 0.5× | 1.3k 1.6× | 428 0.9× | 110 | 6.7k | ||
| Constantinos H. Davos Greece | 38 | 3.7k 0.9× | 856 0.9× | 925 1.1× | 359 0.4× | 546 1.1× | 94 | 5.7k | ||
| Robert N. Doughty New Zealand | 44 | 6.4k 1.5× | 994 1.1× | 490 0.6× | 860 1.1× | 764 1.6× | 212 | 8.4k | ||
| Solomon Behar Israel | 42 | 3.5k 0.8× | 1.2k 1.3× | 517 0.6× | 924 1.1× | 664 1.4× | 166 | 5.5k |
Countries citing papers authored by Arend Mosterd
Since
Specialization
Citations
This map shows the geographic impact of Arend Mosterd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arend Mosterd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arend Mosterd more than expected).
Fields of papers citing papers by Arend Mosterd
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Arend Mosterd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arend Mosterd. The network helps show where Arend Mosterd may publish in the future.
Co-authorship network of co-authors of Arend Mosterd
This figure shows the co-authorship network connecting the top 25 collaborators of Arend Mosterd. A scholar is included among the top collaborators of Arend Mosterd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arend Mosterd. Arend Mosterd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Fiolet, Aernoud T.L., Eric Boersma, Jan H. Cornel, et al.. (2025). Sex Differences in Permanent Discontinuation of Trial Medication in Chronic Coronary Artery Disease: The LoDoCo2 Trial. Journal of the American Heart Association. 14(5). e040412–e040412.
2.
Fiolet, Aernoud T.L., Andrew Lin, Jacek Kwieciński, et al.. (2025). Effect of low-dose colchicine on pericoronary inflammation and coronary plaque composition in chronic coronary disease: a subanalysis of the LoDoCo2 trial. Heart. 111(23). 1156–1163.
3.
Bax, Willem A., John W. Eikelboom, Arend Mosterd, et al.. (2025). Interleukin-6 modifies Lipoprotein(a) and oxidized phospholipids associated cardiovascular disease risk in a secondary prevention cohort. Atherosclerosis. 405. 119211–119211.
4.
Bax, Willem A., Stefan M. Nidorf, Arend Mosterd, et al.. (2025). Cardiovascular Benefit of Colchicine in Relation to Baseline Risk: A Secondary Analysis of the LoDoCo2 Trial. Journal of the American Heart Association. 14(10). e038687–e038687.
5.
Velthuis, Birgitta K., Peder L. Myhre, Arend Mosterd, et al.. (2024). Predictors of coronary atherosclerosis in middle-aged and older athletes: the MARC-2 study. European Heart Journal - Cardiovascular Imaging. 26(3). 461–470.
6.
Fiolet, Aernoud T.L., Arend Mosterd, Jan G.P. Tijssen, et al.. (2023). Association of Low-Dose Colchicine With Incidence of Knee and Hip Replacements. Annals of Internal Medicine. 176(6). 737–742.
7.
Aengevaeren, Vincent L., Arend Mosterd, Birgitta K. Velthuis, et al.. (2023). Advanced glycation endproducts and dicarbonyl compounds are not associated with coronary atherosclerosis characteristics in middle-aged and older male athletes. European Journal of Preventive Cardiology. 30(Supplement_1).
8.
Burger, P.M., Aruna D. Pradhan, Jannick A N Dorresteijn, et al.. (2023). C-Reactive Protein and Risk of Cardiovascular Events and Mortality in Patients with Various Cardiovascular Disease Locations. The American Journal of Cardiology. 197. 13–23.
9.
Ree, Martijn H. van der, Edith Dieleman, J. Visser, et al.. (2022). Direct Clinical Effects of Cardiac Radioablation in the Treatment of a Patient With Therapy-Refractory Ventricular Tachycardia Storm. Advances in Radiation Oncology. 7(5). 100992–100992.
10.
Mentz, Robert J., Hillary Mulder, Arend Mosterd, et al.. (2021). Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial. Journal of Cardiac Failure. 27(9). 949–956.
11.
Claassens, Daniel M.F., Thomas O. Bergmeijer, Gerrit J.A. Vos, et al.. (2021). Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype. Circulation Cardiovascular Interventions. 14(4).
12.
Hageman, Steven H J, Jannick A N Dorresteijn, Michiel L. Bots, et al.. (2021). Residual cardiovascular risk reduction guided by lifetime benefit estimation in patients with symptomatic atherosclerotic disease: effectiveness and cost-effectiveness. European Journal of Preventive Cardiology. 29(4). 635–644.
13.
Waissi, Farahnaz, Mirthe Dekker, Ingrid E.M. Bank, et al.. (2020). Sex differences in flow cytometry–based platelet reactivity in stable outpatients suspected of myocardial ischemia. Research and Practice in Thrombosis and Haemostasis. 4(5). 879–885.
14.
Fiolet, Aernoud T.L., et al.. (2020). Colchicine in coronary disease: another renaissance of an ancient drug. Cardiovascular Research. 117(1). e4–e6.
15.
Claassens, Daniel M.F., Gerrit J.A. Vos, Thomas O. Bergmeijer, et al.. (2019). A Genotype-Guided Strategy for Oral P2Y 12 Inhibitors in Primary PCI. New England Journal of Medicine. 381(17). 1621–1631.
16.
Mosterd, Arend, Edwin van Velzen, Jos P.M. Wielders, et al.. (2011). Clinical Evaluation of Geriatric Outpatients with Suspected Heart Failure: Value of Symptoms, Signs, and Additional Tests. European Journal of Heart Failure. 13(5). 518–527.
17.
Mosterd, Arend, et al.. (2011). Diagnosis of Heart Failure in Elderly Patients: A Clinical Challenge—Reply. European Journal of Heart Failure. 13(10). 1152–1153.
18.
Borleffs, C. Jan Willem, Aryan Vink, Pieter A. Doevendans, et al.. (2011). Cardiogenetic screening of first-degree relatives after sudden cardiac death in the young: a population-based approach. EP Europace. 13(5). 716–722.
19.
Schroten, Nicolas F., et al.. (2010). High Cumulative Incidence of Cancer in Patients with Cardio-Renal-Anaemia Syndrome. European Journal of Heart Failure. 12(8). 855–860.
20.
Mosterd, Arend, Ralph B. D’Agostino, Halit Silbershatz, et al.. (2000). Trends in the Prevalence of Hypertension, Antihypertensive Therapy, and Left Ventricular Hypertrophy from 1950 to 1989. Survey of Anesthesiology. 44(2). 101–102.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Grzegorz Opolski Breakdown of academic impact, for papers by Filippos Triposkiadis Breakdown of academic impact, for papers by Dimitrios Farmakis Breakdown of academic impact, for papers by Kenneth Dickstein Breakdown of academic impact, for papers by Maarten J. Cramer Breakdown of academic impact, for papers by Franz Weidinger Breakdown of academic impact, for papers by Steen Z. Abildstrøm Breakdown of academic impact, for papers by Constantinos H. Davos Breakdown of academic impact, for papers by Robert N. Doughty Breakdown of academic impact, for papers by Solomon Behar